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«Dubium sapientiae initium» 
(Doubt is the beginning of wisdom) 
René Descartes, Meditationes de prima philosophia 	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RIASSUNTO 
 
Le mutazioni che colpiscono il cotrasportatore per il sodio e cloro (NCC) nel tubulo 
contorto distale del nefrone, sono responsabili della sindrome di Gitelman (GS).  
Quest’ultima è una rara tubulopatia renale autosomica recessiva caratterizzata da 
alterazioni elettrolitiche simili a quelle indotte dal trattamento ad alte dosi con diuretici 
tiazidici.   La co-presenza di ipomagnesemia e ipocalciuria è una delle caratteristiche 
di GS che la distinguono da un’altra tubulopatia renale ipokalemica, la  sindorme di 
Bartter (BS).   Generalmente, i soggetti affetti sono eterozigoti composti con una 
prevalenza stimata di 1 su 40000.  La malattia può essere silente per anni prima di 
presentarsi nell’età adulta.  Riconoscerne la componente genetica è fondamentale per 
lo screening e la diagnosi.  Recenti studi hanno di fatto dimostrato come le mutazioni a 
carico dei regolatori renali dell’omeostasi del sodio siano sottostimate nella popolazione 
generale. 
Nel nostro database universitario di pazienti BS/GS abbiamo riscontrato una nuova 
mutazione puntiforme (c.1204G>A che comporta lo scambio aminoacidico Gly394Asp) 
nel cotrasportatore del sodio e cloro NCC (SLC12A3) in una giovane donna con 
ipokaliemia, ipomagnesemia e ipocalciuria associati a dolori e crampi muscolari.  Il 
presente studio ha lo scopo di investigare tramite un approccio biologico molecolare 
come questa mutazione influenzi la funzionalità di NCC. 
Previo screening con softwares bioinformatici che predicono la possibile patogenicità 
della mutazione, sono stati creati dei vettori di espressione contenenti le sequenze per 
NCC wild type e per NCC con mutazione G394D.  Successivamente, le sequenze sono 
state trasfettate in una linea di cellule fetali umane ricombinate (HEK293) e in ovociti 
derivati da rane Xenopus Laevis.  Nelle cellule trasfettate, l’immunoblotting di NCC 
wild-type ha dimostrato la presenza di due bande approssimativamente a 130 KDa e 
115 KDa che corrispondono rispettivamente alla forma glicosilata e nativa della 
proteina.  Al contrario, G394D-NCC presenta una sola banda a 115 KDa.  Risultati 
simili sono stati ottenuti negli ovociti. In questi ultimi l’immunoistochimica ha inoltre 
mostrato una forte localizzazione di NCC wild-type presso la membrana, mentre NCC 
mutato rimane in compartimenti cellulari interni.  Gli studi funzionali di uptake del 
sodio radioattivo (22Na+) hanno ulteriormente confermato che solo la proteina wild-type 
è in grado di riassorbire il sodio al contrario di G394D-NCC.   
I risultati di questo studio dimostrano come la nuova mutazione puntiforme inibisca la 
funzione di NCC a causa della diminuita capacità della proteina di raggiungere la 
superficie cellulare.  L’assenza di una forma glicosilata matura di G394D-NCC 
suggerisce che la mutazione ne condizioni il folding e ne provochi la ritenzione nel 
reticolo endoplasmico ove vengo attivati processi di degradazione anticipata. 
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SUMMARY 
 
Mutations affecting the sodium-chloride cotransporter (NCC) in the distal convoluted 
tubule of the nephron are causative of Gitelman’s syndrome (GS), a rare autosomal 
recessive disease characterized by electrolytic alterations similar to those induced by 
high dose thiazide treatment.  Notably, the co-existence of hypomagnesemia and 
hypocalciuria is a feature of GS which is a distinguish hallmark from another 
hypokalemic renal tubulopathy, the Bartter’s syndrome (BS).  Commonly GS is 
heterozygous compound with an estimated prevalence of 1:40000 and can be silent for 
years before the revealing in the early adulthood.  Recognizing the genetic background 
is fundamental for the screening and the diagnosis of the disease, as recently studies 
showed that mutation affecting regulators of renal salt handling are underestimated in 
the general population.   
In a registry of BS/GS based at our University we discovered a novel point mutation 
(c.1204G>A which codify for an amino acid exchange G394D) in the sodium-chloride 
cotransporter NCC (SLC12A3) in a young woman with hypokalemia, hypomagnesemia 
and hypocalciuria associated to muscle pain and cramps.  The present study aimed to 
investigate how this mutation affects NCC function by using a molecular biology 
approach and providing functional evidences. 
After a prior screening with bioinformatics tools predicting the possible pathogenicity 
of the mutation, were created different expression vectors with either the wild-type (wt-
NCC) or the mutated G394D-NCC sequences.  DNA and in-vitro transcribed RNA 
were afterwards transfected in a human embryonic kidney cells line (HEK293) and 
injected into oocytes deriving from Xenopus Laevis frog respectively.  In transfected 
HEK 293 cells, wildtype NCC was detected by immunoblotting as two bands at 
approximately 130 kDa and 115 kDa corresponding to fully and core-glycosylated 
NCC, respectively.  In contrast, G394D-NCC was seen as a single band at about 115 
kDa only, suggesting an impaired maturation of the mutated protein. Similar findings 
were made in the oocyte expression system.  Confocal microscopy on the oocytes, did 
also show a strong cell surface localization of wildtype NCC while mutated NCC was 
retained at intracellular compartments.  Consistently, a decent thiazide-sensitive 22Na+ 
uptake into injected oocytes was only found for wildtype but not mutated NCC.   
Taken together all the findings in this study, a novel GS point mutation has been 
characterized to diminish NCC function by impairing trafficking of the protein to the 
cell surface.  The absence of any mature glycosylation form of G394D-NCC suggests 
that the mutation impairs protein folding leading to a retention of NCC in the 
endoplasmic reticulum. 
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INTRODUCTION 
 
Gitelman’s syndrome (GS, OMIM no. 263800) is an inherited autosomal recessive renal 
tubular disorder that affects sodium-chloride cotransporter (NCC) in the distal 
convoluted tubule (DCT) of the nephron.  After its first description in 1966, GS was 
found to be far more uncommon then initially held.  In fact, its estimated prevalence is 
about 1:40000, and the heterozygotes carriers involves about 1% in Caucasian 
populations.  Thus GS is one of the most frequently inherited renal tubular disorders 
(1).  The clinical features of GS usually manifest in adolescence or early adulthood, 
and entail muscle weakness, fatigue, joint pain, cramps and tetany (2).  Its biochemical 
hallmarks comprise hypokalemia, metabolic alkalosis, sodium wasting, co-existence of 
hypomagnesemia and hypocalciuria, and normal or low blood pressure values, the latter 
occurring despite a prominent activation of the renin-angiotensin-aldosterone system  
(RAAS) (3).  The molecular basis of GS was attributed to mutations of the solute 
carrier family 12 member 3 gene SLC12A3 gene, which cause loss-of-function of the 
NCC in the distal convoluted-tubule with renal sodium wasting triggering adaptive 
mechanisms in the kidney, including aldosterone-driven increased excretion of K+ in 
exchange for Na+.  
Of note, the biochemical abnormalities of GS are reproduced pharmacologically by 
administration of thiazide diuretics which inhibit the NCC activity causing sodium and 
potassium wasting, hypovolemia, and RAAS activation.  Thus, patients chronically 
treated with these agents can be regarded as the counterpart of the naturally occurring 
GS.  Owing to their pathophysiologic consequences, GS mutations might blunt the 
hypertension phenotype in essential hypertensive patients, which conceivably led to 
underestimate the prevalence of GS mutations inasmuch the syndrome is usually sought 
for only in patients with hypotension.  Indeed, a screening of 2492 members of the 
Framingham Heart Study (FHS) for variation in three genes causing Bartter’s 
syndromes and variation in SLC12A3 gene, allowed the detection of 138 coding 
sequence variants. Those carrying the mutations had significantly lower age- and sex-
adjusted systolic and diastolic BP compared to the non-carriers (4).  While supporting 
the concept that alleles that alter renal salt handling affect BP variation in the general 
population, these results suggest that genetic testing for these syndromes could become 
part of the assessment of patients with BP disorders in the future. 
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The cloning and characterization of the SLC12A3 gene encoding the NCC unveiled 
several mutations affecting the whole protein gene occur in GS and leading to 
dysfunction of the cotransporter (5,6).  To date, more then 180 mutations in SLC12A3 
are found in the HGMD database (www.hgmd.cf.ac.uk), including missense, nonsense, 
frame-shift and splice site.  Notwithstanding the large number of mutations, the 
molecular mechanisms whereby they impair the function of the NCC still remains 
unclear in most cases as most of the mutations were not functionally characterized.  
The described mutations are in the literature as affecting the cotransporter activity (by 
impairing synthesis of the protein), the trafficking of the cotransporter to the cell 
surface, the function of the protein itself at the cell surface, and finally by enhancing the 
degradation of the protein.  According to some studies the central domain of NCC 
would determine ion translocation and confer thiazide-binding specificity, which could 
account for the pathogenic role of these missense mutations (7).  
The syndrome was first described in 1966 when Gitelman reported the clinical case of 
two sisters who presented muscle weakness and had suffered for many years from a 
chronic dermatitis characterized by thickening with a purple-red hue that could have 
been related to magnesium deficiency (2,8,9).  Successively Spencer and Voyce 
reported four siblings of another family: two of them had hypokalemia, 
hypomagnesaemia and decreased urinary calcium output with episodes of tetany, while 
other members were normal (10).  The concept of “familial hypokalemia and 
hypomagnesemia disorder” due to nonspecific illness had more reports after its first 
description with a growing of symptoms.  In 1992 Zagarra et al described a 33-year-
old woman who presented with hypokalemia-hypomagnesemia associated with renal 
potassium and magnesium wasting (11).  She had normal plasma calcium and normal 
serum calcitriol and parathyroid hormone.  Moreover, a test with intravenous 
furosemide (a loop diuretic) evidenced abolition of hypocalciuria, but exaggerated 
natriuresis and magnesium excretion.  The dissociation of renal calcium transport from 
magnesium transport, together with sodium wasting, suggested the presence of a defect 
in the distal tubule rather than in the loop of Henle.  Furthermore, the patient had 
episodes of tetany and muscle cramps consistently with the syndrome of renotubular 
hypomagnesemia-hypokalemia with hypocalciuria, at that time already known as 
Gitelman's syndrome (GS) (11).  For many years it remained challenging to 
discriminate Gitelman’s from Bartter’s syndrome (BS), which was previously described 
by Bartter et al in 1962 as hypokalemic alkalosis, aldosteronism, hyper/normocalciuria 
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disorder (12-14).  Considering the phenotype, the two syndromes share similar 
features, except for the co-existence in GS of hypokalemia, hypomagnesemia and 
hypocalciuria.  Moreover, subjects affected by GS have a prolongation of the QT 
interval on electrocardiogram and episodes of calcium pyrophosphate crystal deposition 
or chondrocalcinosis (13,15,16).  
The onset time for the symptoms come in adulthood, or adolescence in some cases, 
while BS has a neonatal form, or classically appears in childhood (14,17).  Clinically, 
GS has electrolyte abnormalities similar to those induced by treatment with Thiazide 
diuretics or other drugs that inhibit the Na-Cl cotransporter in the distal convoluted 
tubule (DCT) of the kidney.  In 1996 Simon et al. were describing and characterizing 
some cotransporters and channels involved in the reabsorption of electrolytes to better 
gain insight in hypertension etiology (17-19).  Assembling together the findings that in 
GS the reabsorption of the sodium and chloride occurred in the distal convoluted tubule 
in spite of the loop of Henle, and the concurrent hypomagnesemia and electrolytic 
impairment caused by thiazide treatment, Simon et al. could demonstrate a linkage 
between GS and the sodium-chloride cotransporter (NCC) (20).  They identified a 
great amount of variants in the SLC12A3 gene, encoding for the NCC, which were of 
loss-of-function alleles.  The genetic component in this syndrome is intriguing.  It is 
known to be a rare autosomal recessive disease with a prevalence of 1:40000 with 
heterozygous compound, resulting in the most common frequent inherited renal tubular 
disorder.  It is listed in the Mendelian Inheritance in Men (OMIM) with the number 
268300 (http://omim.org/entry/263800) (1,18).  
In heterozygous condition one of the two alleles present a mutation and the subject is a 
carrier non symptomatic.  In homozygous both alleles are presenting the same 
mutation in the same loci and the subject is presenting the disease. In the heterozygous 
compound both alleles are affected by two different mutations in distinct loci (21).  As 
clinical outcome, it can arise a milder form of the disease [Figure1].  
A	   B	   	   C	   	  
FIGURE1: Schematic representation of autosomes. Boxes indicate alleles, black rectangles 
indicate mutations. A Heterozygous genotype B Homozygous genotype C Homozygous 
compound genotype 
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Additionally, GS differs from BS for the genetic trait.  While GS is identified as a 
monogenic disease due to mutations affecting NCC, BS is usually classified in 5 types 
regarding the protein affected with an earlier onset timing.  The electrolyte 
abnormalities of BS are similar to those induced by treatment with furosemide or other 
loop diuretics that inhibit the Na-K-2Cl (NKCC2) cotransporter of the thick ascending 
limb of Henle’s loop (TAL).  Typically, NKCC2 mutations classify BS type I.  Other 
mutations are found in genes involved in the regulation of NKCC2 activity, in 
particular, alterations in the apical ATP-sensitive K channel (renal outer medullary 
channel, ROMK) arise BS type II; mutations in the chloride channel Kb (ClCNKb) 
identify BS type III and furthermore, its regulatory protein Barttin can also be affected 
causing BS type IV.  Type V BS is induced by mutations in the Ca2+ sensing receptor 
(CaSR) (14,17-19). [Figure2]  
	   	   	   	   	   	   	   	   	   A	   	   B	  
FIGURE 2: A Distal convoluted cells in Gitelman’s syndrome. Mutations affect the Na-Cl 
cotransporters. B Thick ascending limb cells in Bartter’s syndrome. Mutations affect different 
cotransporters or channels identifying different types. 
 
Recently, a novel form of Bartter syndrome has also been described by Laghmani et al. 
as a transient antenatal form with polyhydramnios and mutations in the MAGED2 
which encodes melanoma- associated antigen D2 (22). 
Both GS and BS syndromes are characterized by marked RAAS stimulation featuring 
high plasma renin, angiotensin II (Ang II) and aldosterone. Notwithstanding this 
activation, patients show reduced peripheral resistance and normal to low blood 
pressure, along with resistance to the pressor effect of vasoconstrictors as Ang II and 
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norepinephrine (23).  Hence it has been speculated, that heterozygous carriers of NCC 
mutation are partially protected from hypertension (4,24). 
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ANGIOTENSIN II SIGNALING IN GITELMAN’S SYNDROME 
Studies in GS and BS may provide useful insights on understanding the mechanisms 
involved in the control and regulation of vascular tone and blood pressure in humans.  
In physiological conditions, Ang II is directly involved in activating microvascular 
signaling leading to increased peripheral resistance and hypertension.  Of note, Calò et 
al. demonstrated that GS and BS patients have a blunted signaling of Ang II despite 
higher levels of the hormone and normal Ang II receptors number and affinity (23).  
This suggests that the Ang II signaling is interrupted at the post receptor level or very 
close to the central switch controlling Ang II signals.  Due to their characteristic 
activation of RAAS	  with concomitant low blood pressure, the two syndromes can be 
viewed as ‘‘mirror image’’ of hypertension and as human model of endogenous 
antagonism of Ang II signaling via AT1R [Table 1]. 
 
TABLE 1: Opposite effects of Angiotensin II signaling in BS/GS and in Hypertension. In 
hypertensive conditions, AngII signaling through AT1R promotes oxidative stress-related 
pathways, whereas in BS/GS the binding of AngII with AT2R induces favorable anti-
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remodeling and anti-proliferative effects. Adapted from Ravarotto et al. High Blood Press 
Cardiovasc Prev (2015) 22:215 
 
The multiple effects of Ang II function involve short or long-term signaling. The short-
term signaling pathways are mediated by monomeric and heterotrimeric G proteins and 
phospholipase Cb (PLCβ). The bind of Ang II to its receptor AT1 promote the release 
of intracellular messengers inositol triphosphate (IP3) and Ca2+, generation of 
superoxide and activation of protein kinase C (PKC) with ensuing vascular smooth 
muscle contraction (8).  A counterbalancing system is represented by the nitric oxide 
(NO) system, which has vasodilatory and antiproliferative activity.  NO is released by 
endothelial NO synthase (eNOS) and is negatively regulated by PKC.  Therefore, the 
effect of Ang II on vascular function and structure is the result of the net balance of 
signaling molecules, oxidative stress and gasomessengers as nitric oxide (25,26). 
The long-term effects of Ang II promote proliferation and cardiovascular-renal 
remodeling mostly through the induction of oxidative stress (27,28).  The complex of 
Ang II with the AT1 G-protein-coupled receptors promotes alongside the increase of 
free intracellular Ca2+, the activation of the RhoA/ Rho kinase pathway with subsequent 
vasoconstriction and insulin resistance (5). [Figure 3] 
In hypertension Gq and Gi proteins mediate the activation of the PLC.  The Ang II-
AT1R complex couples with PLCb and promotes activation of PKC and 
phosphorylation of the regulatory chain of myosin II.  In addition, the activation of the 
monomeric G-protein RhoA and its effector Rho kinase modulates the phosphorylation 
state of the regulatory chain of myosin II, mainly through inhibition of the myosin 
phosphatase target protein-1 (MYPT-1).  These pathways induce vasoconstriction and 
increased peripheral resistance, while at the same time NO pathway is reduced (23). 
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FIGURE 3: Schematic representation of Ang II signaling pathways involved in 
hypertension and complications (changes of cardiovascular structure: remodeling and 
atherogenesis; hypertension-inflammation relationship; hypertension-glucose transport 
and insulin resistance and sensitivity interrelationships). Ang II, angiotensin II; AT1-R, 
angiotensin II type 1 receptor; [beta] and [gamma] subunit of Gq protein; DAG, 
diacylglycerol; eNOS, endothelial subunit of nitric oxide synthase; PIP2, inositol 
triphosphate; PKC, protein kinase C; PLC[beta], phospholipase C [beta]; RhoGEF, Rho 
guanine nucleotide exchange factor; ROCK, Rho Kinase; MYPT, myosin light chain 
target subunit-1. Adapted from Calò et al. J. Hypertens 32(11):2109-2119, November 
2014 (23) 
 
Ang II signaling in GS and BS is reversed: subjects affected have decreased gene and 
protein expression of the α subunit of Gq protein and blunted downstream intracellular 
events that promote Ca2+ release and PKC activation in the short-term pathway of Ang 
II (29,30) In addition, in these patients the evaluation of the NO system via the 
endothelial nitric oxide synthase (eNOS) mRNA levels, urinary excretion of NO 
metabolites and NO mediated vasodilation showed a significant increase of eNOS 
expression, and an increased NO mediated vasodilation compared with hypertensive 
patients (31-33).  
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The long-term network for GS and BS is characterized by underexpression of pro-
oxidant elements, in favor of an antioxidant potential which is demonstrated by the 
augmented expression of heme oxygenase 1 (HO-1) and NOX4 and reduced p22phox 
(34,35) [Figure 4] 
	  
FIGURE 4: Ang II signaling and its relationships with nitric oxide, RhoA and Rho kinase and 
oxidative stress systems in GS and BS. In green highlighted the antioxidant and antiremodeling 
potential. Ang II, angiotensin II; AT1-R, angiotensin II type 1 receptor; [beta] and [gamma] 
subunit of Gq protein; CO, carbon monoxide; DAG, diacylglycerol; eNOS, endothelial subunit 
of nitric oxide synthase; ET-1, endothelin-1; G[alpha]q, [alpha] subunit of Gq protein; HO-1, 
heme oxygenase-1; IP3, inositol triphosphate; MAPK-ERK 1/2, mitogen-activated protein 
kinases; NE, norepinephrine; PI3K-Akt, phosphatidyl inositol 3-kinase-Akt (protein kinase B); 
PKC, protein kinase C; PLC[beta], phospholipase C [beta]; P-MLC, phosphorylated myosin 
light chain; RGS-2, regulatory of the G protein signaling-2; RhoGEF, Rho guanine nucleotide 
exchange factor; Continuous lines represent stimulation. Dashed lines represent inhibition 
Adapted from Calò et al. J. Hypertens 32(11):2109-2119, November 2014.  (23)  	  
The sodium-chloride cotransporter is a member of the big class of solute carrier proteins 
(SLC) which include 43 families and 298 transporter genes. [Table 2]  In particular, it 
belongs to the SLC12 of the electroneutral cation-chloride cotransporters and it is 
encoded by the gene SLC12A3 (36).  The SLC12A3 gene transcript variant 1 encodes 
for human sodium-chloride cotransporter and contains 26 exons with 5582 bp 
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(NM_000339.2).  In situ hybridization experiments showed the presence of the 
encoding sequence for NCC on the long arm of chromosome 16 region 13 (16q13) (37).  
SLC12A3 shares a highly conserved aminoacid sequence with other members of the 
family, which features twelve transmembrane portions harboring a central hydrophobic 
domain and two cytosolic terminal ends (NH2 and COOH) (38). [Figure5] 	  
The central region seems to be highly specific for ion translocation and for thiazide-
binding, particularly the 7th and 8th domains, which entail the external loops 
fundamental for glycosylation sites (38,39). 
 
 
 
FIGURE 5: Schematic representation of the Na-Cl cotransporter. The N-terminus and C-
terminus are in the cytosolic compartment, while the extracellular loop comprised between the 
7th and the 8th transmembrane helical traits contains two glycosylation sites (Asparagine 404 and 
424). 
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TABLE 2: List of the Solute Carrier Families 
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Approximately 400 mutations are described to affect the cotransporter and cause GS. 
Most of them (~250) are missense [human gene mutation database hgmd.cf.ac.uk] and 
are spread all along the whole protein.  More than 50 mutations have been reported 
only in Asian populations (38).    
Although there are some functional evidences of the impaired activity of NCC mutated, 
the mechanistic bases of them are still not elucidated yet.  	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THE ROLE OF NCC IN BLOOD PRESSURE CONTROL 
NCC is expressed in the apical membrane of the distal convoluted tubule (DCT) in the 
kidney where it allows Na+ and Cl- reabsorption across the luminal plasma membrane 
(40-42).  
According to an extended structural analysis of the tubules segments, the DCT is the 
nephron segment that lies immediately downstream of the macula densa and plays a 
critical role in a variety of homeostatic processes, including sodium chloride 
reabsorption, potassium secretion, and calcium and magnesium handling.  Moreover, it 
has the capacity to adapt to changes in both hormonal stimuli and the tubular lumen 
content, thus being fundamental in the control of blood pressure as in the fine tuning of 
ions excretion (43,44).  
Based on expression of the different transporters, DCT can be distinguished in two 
portions: the early DCT (or DCT1) and the late (or DCT2) (43).  NCC is distributed in 
the DCT1 along with the magnesium channels (TRPM6) and in little part in the DCT2. 
The DCT2 shows also other proteins, as the target of Aldosterone epithelial sodium 
channel (ENaC), epithelial calcium channels (TRPV5), the sodium-calcium exchanger 
(NCX), plasma membrane calcium-ATPase (PMCA), cytoplasmic calcium-binding 
protein calbindin D28k and intercalated cells (45-48). [Figure 6]  
 
 
FIGURE 6: schematic representation of DCT1 and DCT2 cells expressing different proteins. 
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Only 5-10% of the Na+ load is reabsorbed in the distal convolution and in the 
connecting tubule (CNT) and micropunture experiments showed that, while the early 
DCT is sensitive to thiazides, the late DCT is an amiloride-sensitive segment due to the 
presence of ENaC (49).  The Na+ transport in the DCT1 is electroneutral considering 
the co-transport of Na+ and Cl- trough NCC, while in DCT2 ENaC arise to a negative 
charge in the tubular lumen for its electrogenic transport of Na+.  The functional 
significance of a double Na+ reabsorption is testified by the observation that in low salt 
experimental condition, ENaC is increased to maintain Na+ balance (49).  As 
counterpart, to restore a neutral charge in the lumen, potassium secretion is enhanced 
trough ROMK channels or intercalated cells (43).  The interplay between Na+ 
reabsorption and K+ secretion is fundamental to understand pathological conditions, in 
which there is a gain-of-function or a loss-of-function of certain proteins.  NCC loss-
of-function mutations lead to Na+ dissipation, which in turns stimulate a gradient for 
water to exit, whereas ENaC overactivates to restore the Na+ intake. Finally, to replace 
the ionic imbalance in the tubular lumen, ROMK drives K+ out leading to hypokalemia.  
On the contrary, in gain-of-function conditions, overstimulation of NCC prompt to 
hypertension and hyperkalemia can be observed in patients with 
pseudohyperaldosteronism type II (Gordon’s syndrome) (50).  
Cotransporters and channels coordination is the driving force that permit the fine tuning 
of ions in the DCT.  Magnesium absorption through TRPM6 is potentiated by apical K 
channel Kv1.1 which generates the lumen negative potential.	   Basolateral K channel 
Kir4.1 and the of Na,K-ATPase also increase magnesium reabsorption by creating a 
sodium gradient, enabling NCC to transport sodium from the apical lumen to the 
cytosol (Blaine).  
As the over-activation of RAAS is a feature of Gitelman’s syndrome, the presence of 
high plasma aldosterone levels burden on the DCT, but the effect may differs along the 
axis of the distal convolution (42).  Studies in rat demonstrated that MR is present in 
the DCT and in the CNT, albeit the enzyme 11β-hydroxysteroid dehydrogenase type 2 
(11β-HSD2 which in turns, inactivates glucocorticoids that would otherwise occupy 
aldosterone receptors), seems to be detectable only in the late DCT (50,51).   
Studies in rat showed that whereas MR seems to be present throughout the DCT and 
CNT, 11β-HSD2 is not detectable in the early DCT1 but is well detectable in the late 
DCT (DCT2), in the CNT, and CD(47,52).  These investigations suggest that 
aldosterone may stimulate sodium-transport mainly in the DCT2 where ENaC, NCC, 
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MR and 11β-HSD2 are expressed, while in the early DCT, NCC activity could be 
stimulated by mineralcorticoids and glucocorticoids in combination (53).   
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FUNCTIONAL STUDIES 
Transfection experiments can be regarded as a powerful strategy to understand gene 
function and have been widely used to highlight many biological issues. By transfection 
technique is possible to introduce exogenous genetic information in a host cell in order 
to induce the production of certain protein and more generally to study biochemical 
pathways.  The methods in which the DNAs or RNAs are delivered varies according to 
the purpose and the host chosen. Ideally, procedures should have high transfection 
efficiency, low cell toxicity, minimal effects on normal physiology, and be easy to use 
and reproduced (54). 
Three typical transfection methods exists: the biological, the chemical and the physical, 
each of them presenting advantages and disadvantages.  Biological methods are 
performed by inserting viral vectors in the host.  The viral DNA integrates randomly in 
the host genome and permits a high efficiency in terms of transfection, nevertheless, 
during the process some mutations not predicted can arise, leading therefore to a final 
abnormal cell (55).  Chemical methods are the most commonly used for their easiness 
of procedure and no contamination of genetic information, but still the efficiency can 
vary for a considerable number of factors.  The ratio between chemicals and DNA, the 
cells growth rate, pH of the solutions and the timing of the experiments influence the 
response.  Among chemical transfections can be considered cationic polymer (one of 
the oldest chemicals used), calcium phosphate, cationic lipid (the most popular method), 
and cationic amino acid (56). Micro injection, biolistic particle delivery, 
electroporation, and laser-based transfection are physical procedures to deliver 
exogenous DNA but can be expensive and need a arrangement of the protocols (57).  
 
Ø HUMAN EMBRYONIC KIDNEY CELL LINE  
HEK293 is a cell line derived from human embryonic kidney cells grown in tissue 
culture. They have been originally transfected with the calcium phosphate medium 
exposure for 3 days and later on with low calcium ion medium, to and Adenovirus type 
5 purified DNA (Ad5 DNA) of approximately 4.5 kilobases.  After the viral 
transfection, the HEK293 cell line showed significantly disrupted cell morphology with 
a tendency to growth in clumps and to replicate fast (58). 
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One of the most well established method of transfection is lipofection. [Figure 7]. The 
underlying principle is that positively charged chemicals complexes with negatively 
charged nucleic acids. These positively charged complexes are attracted to the 
negatively charged cell membrane. To date, no experimental evidences clarified how 
the complexes pass through the cell membrane; however, supposedly this occurs via 
endocytosis.  
	  
FIGURE 7: Schematic process of lipofection. The negative charged DNA binds the positively 
charged liposomes. The complex is thus attracted by the cell membrane. Once in the cytosolic 
compartment, the complex releases the DNA which in turns enters into the nucleus of the host 
and codify for the specific information introduced. 
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Ø XENOPUS LAEVIS OOCYTES IN BIOLOGY 
	  
	  	  	  
Xenopus is a genus of African frogs that are commonly known as the African clawed 
frogs.  Originally frogs were used as a test for pregnancy by revealing the presence of 
chorionic gonadotropin released in women urines (59).  After stimulation by the 
hormone, frogs produce a huge number, often thousands, of eggs (also defined oocytes) 
and this indicated the presence of gestation.  X.L. oocytes are therefore, a useful tool 
for biochemical investigation, especially of membrane transporters and channels (60).  
The oocytes have a diameter of 1.2 mm which permits to manipulate them easily.  
During the first stages of development they are rich in RNA and proteins and they lack 
of a transcriptional activity until the mid-late blastula stage.  Visually they appear 
divided in two hemispheres, the vegetal pole and the animal one. The vegetal pole is 
white colored and is characterized by the presence of yolk cells organized in a blastula 
with slow division.  The animal pole, the darker and opaque hemisphere, consists of 
small cells that divide rapidly (61).  
The elevated number of eggs produced can be easily conserved in a saline solution and 
manipulated by injecting exogenous material as DNA codifying for one or more 
proteins of interest (59).  The step by which the procedure undergoes start from a 
sorting of the “visually healthier” eggs from the batch, followed by a defolliculation 
phase by either enzymatic or manual treatment (62). [Figure 8] 
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FIGURE 8: Process of defolliculation of Xenopus Laevis oocytes. The dark and the white 
hemispheres indicate the animal pole and the pole respectively. 
 
After the defolliculation step, which removes the follicle layer anchored to the vitelline 
one, RNA can be injected.  X.L. oocytes are being successfully used to investigate ions 
channels and cotransporters activity, because of their low level of endogenously 
expressed channels and receptors, which yields a relatively electrophysiologically silent 
background.  Moreover, they also carry the cellular apparatus to produce functionally 
post-translational modifications (63).  	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AIM OF THE STUDY 
 
This study aims to characterize the molecular and functional effects of a novel point 
mutation (c.1204G>A) that was found in a GS case, never described before.  The 
mutation causes the aminoacid exchange Gly394Asp in the 7th transmembrane domain 
of the cotransporter, which is an important site close to the two glycosylation residues 
of the protein.  In order to assess the impact of this exchange on the activity of the 
protein, the study has been conducted following the study design: 
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MATHERIALS AND METHODS 
 
Investigation strategy 
 
 
 
 
After the genetic screening the patient has been afterwards diagnosed for GS.  In order 
to predict the possible impact of the novel mutation in the activity of the cotransporter 
has been conducted a research by using bioinformatics tools.  Taking into account all 
the results, construct expression vectors enclosing the genetic information for either 
NCC wild-type and NCC mutated (G394D-NCC) have been created.  After 
optimization of the protocols, constructs have been transfected in HEK293 cells in 
which the grade of protein expression has been evaluated by immunofluorescence and 
western blot.  Beside the in vitro experiments, oocytes coming from Xenopus Laevis 
frog have been injected with the constructs and have been used for 
immunohistochemistry analysis, western blot and for 22Na+ uptake experiments. 
 
 
  28	  
Molecular Investigation 
After a clinical diagnosis of Gitelman’s syndrome, was made a genetic test was done to 
confirm the diagnosis and identify possible mutations on the SLC12A3 gene.  This 
was done at the Laboratory of Medical Genetics (Ospedale Maggiore Policlinico, 
Fondazione IRCCS Ca’ Granda, Milano), certified by the European Molecular Genetics 
Quality Networ (www.emqn.org) 
DNA was extracted from a peripheral blood sample and all 26 exons were analyzed. 
 
Prediction of mutation influence   
Phenotypic effects of amino acid substitution on protein function were predicted by 
online bioinformatics tools.  At least two of them should give an indication of potential 
impairment.  
I-Mutant2.0, (http://folding.biofold.org/i-mutant/i-mutant2.0.html) to predict the 
stability; Polyphen-2 (http://genetics.bwh.harvard.edu/pph2/) to predict the 
pathogenicity and Sorting intolerant from tolerant SIFT (http://sift.jcvi.org) to predict 
the activity of the protein mutated ) (64-66).  To confirm the results of SIFT, an 
additional tool was used: the Protein Variation Effect Analyzer (PROVEAN, 
http://provean.jcvi.org/index.php).  The latter, accepts a protein sequence and amino 
acid variations as input, performing a BLAST search to identify homologous sequences 
(supporting sequences), and generating PROVEAN and SIFT scores. 
 
Synthesis of wt-NCC and G394D-NCC cRNA  
cDNA (GeneCopoeia, Rockville, USA) of human wild-type (wt-NCC) and mutated 
NCC (G394D-NCC) were cloned in pSDeasy vector.  After linearization of the 
plasmid with PciI (New England Biolabs) cRNA synthesis was performed using the 
MEGAScript SP6 kit (ambion; USA) following the manufactures instructions. cRNA 
was purified (Nucleospin RNA; MacheryNagel, CH) and the integrity of the 
transcription product was confirmed by agarose gel electrophoresis.  
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cRNA injection in X. laevis Oocytes  
X. laevis oocytes of stage IV-V were injected with 0.05µl cRNA (44µg/µl) of wt-NCC 
and G3964D-NCC respectively or, as a control, with 0.05µl H2O.  Oocytes were 
incubated at 16°C for 72 h in modified Barth’s Solution (NaCl 88mM, KCl 1mM, CaCl2 
0.41mM, MgCl2 0.82mM, Ca(NO3)2 0.33mM, NaHCO3 2.4 mM, HEPES/Tris 10 mM, 
pH 7.4) with gentamycin (5mg/l) and Doxy for translation of the protein. Solutions 
were changed daily.  After 72 h oocytes were processed to analyze NCC expression, 
trafficking and activity by western blot, immunohistochemistry and 22Na+-uptake 
experiments respectively. 
 
Western blot  
For Western blot experiments, 3 to 10 oocytes per group were pooled and lysed in 30 to 
100 µl lysis buffer (10µl lysis buffer/oocyte; 250mM Sucrose; 0.5 mM EDTA, pH8; 5 
mM Tris-HCl, pH 6.9; Protease Inhibitor (Roche Diagnostic; Mannheim, D) and 
Phosphatase Inhibitor (Roche Diagnostic; Mannheim, D)).  Proteins (an equivalent of 
one oocyte per lane) were separated in a SDS-PAGE gel and transferred on 
nitrocellulose membrane. Membrane was blocked by odyssey blocking buffer and NCC 
was detected with an antibody against the N-terminal tail of NCC (1:4000; Millipore) 
followed by a goat anti rabbit IRD800 (1:20’000; LI-COR, Bad Homburg, Germany) 
and subsequent imaging with the LI-COR system (LI-COR, Bad Homburg, Germany).  
Equal protein loading was controlled by immunodetection of GAPDH with a mouse 
monoclonal antibody (1:4000; Ambion, Carlsbad USA) 
 
Immunofluorescence  
For immunofluorescent studies, oocytes were fixed with 3%PFA in 0.1M phosphate 
buffer (pH7.3; 300 mosm) for 4 hours at 4°C and rinsed in phosphate buffer for an 
additional 2 hours.  Afterwards, oocytes were frozen in liquid propane, stored at -
80°C, and then processed for immunofluorescence similar to previously described 
procedures (67).  In brief, frozen oocytes were cut in a cryostat in 5 µm thick sections. 
Unspecific binding sites were blocked with 10% normal goat serum and 1% bovine 
serum albumin in PBS.  Cryosections were incubated overnight at 4°C with an 
antibody against the N-terminal tail of NCC (1:2000; Millipore).  Binding sites of the 
first antibody were detected using a CY3 labelled goat-anti-rabbit antibody (1:1000; 
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Jackson Immuno Research, West Grove, PA, USA.  The cell surface of the oocytes 
was labeled by detecting the microvillar actin cytoskeleton with Fluorescein Phalloidine 
(1:50; Biotium, Hayward, USA).  After repeated washings, sections were cover 
slipped and studied with a fluorescence microscope (Leica DM6000 B).  Images were 
acquired with a CCD camera and processed by Adobe Photoshop and Microsoft Power 
Point software. 
 
22Na+-uptake experiments 
For 22Na+ uptake experiments was followed the protocol from Monroy et. al. (2001) 
(68).  72h after infection, oocytes were washed and incubated for 30 minutes at 30°C 
in isotonic K+- and Cl--free medium (Na+-gluconate, 96mM; Ca2+-gluconate, 6mM; 
Mg2+-gluconate, 1mM; HEPES/Tris (pH 7.4), 5mM; ouabain, 1mM, bumetanide, 100 
µM; amiloride 100 µM).  Uptake was performed at 30°C for 60 minutes in an isotonic 
K+-free medium (NaCl, 96mM; CaCl2, 1.8mM; Mg Cl2, 1mM; HEPES (pH 7.4), 5mM; 
ouabain, 1mM, bumetanide, 100 µM; amiloride 100 µM) supplemented with 2 µCi/ml 
22Na+ (Perking Elmer, Waltham, MA, USA).  To determine thiazide dependent 
sodium-uptake, uptake was performed in presence or absence of a thiazide-like diuretic 
(100µM Metolazone in DMSO; Sigma-Aldrich).  22Na+ uptake was terminated by 
washing the oocytes 6 times in ice-cold K+-free medium to remove extracellular 22Na+.  
Oocytes were individually lysed in 10% SDS.  Radioactive tracer was detected in a 
liquid scintillation analyzer (Packard TRI-CARB 2000/2200CA; PerkinElmer, USA). 
Results of three individual experiments were pooled (wt-NCC (Nno Thiazide=44; 
NThiazide=46), G394D-NCC (Nno Thiazide=44; NThiazide=42), H2O (Nno 
Thiazide=43; NThiazide=44)). 
 
In vitro experiments 
The human embryonic kidney cell line HEK-293 (American Type Cell Culture, ATCC, 
Manassas, VA), which was originally transformed by exposing cells to sheared 
fragments of adenovirus type 5 DNA (58), was used as a model of kidney cells for the 
ease of growth and transfection efficiency.   Cells were cultured in Eagle's Minimum 
Essential Medium added with 10% fetal bovine serum (FBS) (Sigma Aldrich) in 
Corning® T-75 flasks at 37°C and 5% CO2.  After replication of expression vectors 
ORF cDNA clones (GeneCopoeia, Maryland, USA) by bacteria, wt-NCC, G394D-NCC 
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and green fluorescent protein (GFP) DNAs were transfected into the cells by lipofection 
technique using Metafectene® (Biontex Laboratories GmbH, München, D).  
Lipofection technique was chosen for its high efficiency, low toxicity and high 
reproducibility established in our laboratory. After protocol optimization cells were 
stimulated cells at 24 and 48 hours of transfection.  
 
Immunoblotting 
To evaluate NCC protein expression proteins were extracted from the cells transfected 
by using a lysis buffer (150mM NaCl, 50mM Tris-HCl pH 8.00, 1% Triton-X-100, 
Protease and Phosphatase Inhibitors, Roche, BS, Switzerland).  To quantify proteins, a 
Bradford assay with standard protocol was performed (CooAssay Protein Dosage 
Reagent, Uptima, France).  Protein samples were separated in an 8% polyacrylamide 
gel.  After electrophoretic separation, proteins were transferred to nitrocellulose 
membranes which were then blocked for 30 minutes in blocking buffer (Odyssey 
blocking buffer, Li-Cor Biosciences, USA) and incubated with primary antibodies 
against NCC (Millipore) diluted 1:4000 at 4°C overnight.  Membranes were further 
incubated for 2 h with goat anti rabbit IRD800 (1:20’000; LI-COR, Bad Homburg, 
Germany) diluted 1:10000 and finally visualized by Odissey imager (Li-Cor, Nebraska, 
USA).  A monoclonal antibody against α-tubulin diluted 1:10000 was used for 
normalization.  Images were processed and analyzed using a densitometric 
semiquantitative analysis with NIH image analyzer software (NIH ImageJ; Fiji open-
source). 
 
Immunofluorescence 
To detect whether the cells acquired the plasmids, cells were let growing on glass 
coverslips and after transfection with wt-NCC, G394D-NCC and GFP DNAs, were 
fixed at 4°C with the fixation solution (PFA 3%, PBS pH 7.3).  After over night 
fixation and 3 times washing steps with PBS, cells were pre-incubated with 
PBS/BSA2% 10 minutes, followed by incubation with 0. 5% Triton-100 and washing 
steps, finally incubated with an anti-N-terminal tail of NCC antibody diluted 1:2000 
over night at 4°C. The following day coverslips were rinsed and incubated 2 h at dark 
with a secondary CY3 labelled goat-anti-rabbit antibody diluted 1:1000 (Jackson 
Immuno Research, West Grove, PA, USA), and DAPI diluted 1:1000 and PBS/BSA2% 
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for nuclei staining and after washing steps, the glycerol mounting medium with 
DABCO was added and left 2h at 4°C.  Images were revealed with a confocal Leica 
microscope. Images were acquired with a CCD camera and processed by Adobe 
Photoshop and Microsoft Power Point software. 
 
Power calculation and statistical analysis  
Sample size were preliminarily calculated by ImageJ software, then analyzed with 
GraphPad Prism 5.  A two-way analysis of variance (ANOVA) was used to assess 
both the differences between wt-NCC and G394D-NCC glycosylation and the 22Na+ 
Uptake in the oocytes experiments. 
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RESULTS 
 
Prediction of mutation influence   
The novel mutation found in the index case, is a single nucleotide c.1204G>A (ref. 
NM_000339.2), which induces the exchange of a Glycine with an Aspartic Acid in 
position 394.  The meaning of the mutation can be predicted by using software that 
forecast the possible impact of an amino acid substitution on the structure and function 
of a human protein matching with bioinformatics tools the physical and comparative 
considerations.  I-Mutant2.0, Polyphen-2 and SIFT are three online programs useful to 
predict the stability, pathogenicity and the activity respectively of a mutation 
(http://folding.biofold.org/i-mutant/i-mutant2.0.html, 
http://genetics.bwh.harvard.edu/pph2/, http://sift.jcvi.org).  The relevance of these 
tools, even if there might be some inaccuracy in the results, occurs when it is necessary 
to screen many variants to characterize them.  When the linear amino acids sequence is 
translated into a three dimensional protein structure, it delineates alpha-helices and β-
sheets strands, which tends to arrange in a specific thermodynamically most stable 
conformation (69).  If there is some perturbation of the system, the protein can not be 
folded in the proper shape leading to production of an erroneous peptide. The cell 
machinery deputed to dismantle it is therefore activated.  Alignment of the human 
sequence with other orthologous species, reveals a high degree of conservation, 
especially for the region between the 7th and the 8th transmembrane portions among 
them (37).  
Ø Prediction of NCC mut activity with SIFT and PROVEAN programs:  
SIFT prediction is based on the degree of conservation of amino acid residues in 
sequence alignments derived from closely related sequences.  Those with SIFT score 
≤0.05 were classified as deleterious and those >0.05 were classified as tolerated (doi: 
10.1038/nprot.2009.86).  The mutation in 394 of a Glycine (G) with an Aspartic Acid 
(D) has a SIFT score ≤0.05 thus is classified as not tolerated in a highly conserved 
region. [Figure 9] 
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FIGURE 9: the yellow row highlights the position of the aminoacid exchange. The d in blue is 
the aspartic acid in the right lane, which means that is not accepted as exchange, because if 
would influence in the activity of the protein. 
 
To confirm the result, a PROVEAN job was also submitted using the following input 
format: <protein ID> <position> <reference aa> <variant aa>  
The score of -5.71 (reference value = -2.5) predict a deleterious phenotype, and 
confirmed the SIFT score below the threshold of ≤0.05. [Figure 10]: 
	  
Figure 10: PROVEAN score for the prediction of the impact of a mutation on biological 
function of the protein.  
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Ø Prediction of NCC mut stability with I-Mutant2.0 
I-Mutant software predicts that the mutation destabilizes the free-energy energy leading 
to a protein structure not fixed. [Figure 11] 
	  
Figure 11: The software gives the prediction of decreased stability based on a high reliability 
index (9) at a temperature of 25 °C and pH 7.0. (WT) aminoacid in Wild-Type Protein, (NEW) 
New Aminoacid after Mutation, (RI) reliability Index, (T) temperature in Celsius degrees, (pH) 
–log[H+] 
 
Ø Prediction of NCC mut pathogenicity with PolyPhen-2 
PolyPhen-2 gave a high score, indicating a possible impact as damaging. [Figure 12] 
	  
Figure 12: Image of PolyPhen-2 analysis for the Gly394Asp. The high score of 1.00 indicate 
the amino acid exchange probably damaging. 
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HEK293 Transfection 
Cells were transfected by using liposome technique with three exogenous DNAs 
containing the information of the while type protein, of the mutant respectively and the 
information for the green fluorescent protein (GFP).  Plasmids were produced 
introducing the mutation found in the index case: the nucleotide exchange in position 
1204 of a guanine with an adenine produced therefore an Aspartic Acid in spite of the 
Glycine in position 394.  The folding structure of the cotransporter reveals the 
mutation to be sited near the extracellular loop containing the two glycosylation sites of 
the aa in 404 and 424 [Figure 13].  
A 	  
B 	  
C 	  
FIGURE 13: A. Alignment of the wild-type and the mutant nucleotide sequences. B. 
Alignment of the wild-type and the mutant amino acid sequences. C. Three-dimensional image 
of the sodium-chloride cotransporter NCC. Highlighted in yellow is the point mutation in the 
seventh transmembrane portion, near the extracellular loop. 	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Transfection efficiency was assessed by immunofluorescence in Hek293 cell line using 
cells transfected with genetic information for the green fluorescent protein as control.  
We observed the rate of growth of the cells and, by according to protocol, transfected 
when they were at 70% of visual confluence.  GFP transfected cells were green under 
fluorescence microscope, while those transfected with G394D-NCC or wt-NCC were 
not.  This result indicates that there was no error in the replication and isolation of the 
plasmids.  Moreover, to assess if the genetic information was correctly transmitted to 
the host, immunostaining using an antibody for NCC was performed.  The GFP cells 
did not show any staining for NCC antibody when assessed at the confocal microscope, 
as proof of good quality transfection [Figure 14].  
	  
FIGURE 14: Immunofluorescence on HEK293 with 20X zoom. A: Cells transfected with wt-
NCC. B: Cells transfected with G394D-NCC. C: Cells transfected with EGFP. In blue DAPI 
staining, in red staining for NCC. Cells transfected with EGFP do not show staining for NCC. 	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Ø NCC Glycosylation in HEK293 cells line  
To investigate whether if the novel mutation affects protein glycosylation, both the 
samples treated with wt-NCC and with G394D-NCC were blotted and a difference in 
the proteins glycosylation was observed. Wt-NCC showed a higher band (around 
130KDa), while the mutant did not.  When the two bands were quantified, we found a 
significant difference of the higher band expression at 24 hours (p<0.003 NCC wt mean 
+ SEM 0,233±0.046; NCC mut mean + SEM 0.0268±0.008) in the wild type compared 
to the mutants and an even more prominent difference was at 48 hours of transfection 
(p<0.0003 wt-NCC 0,524±0.084; G394D-NCC 0.059±0.012). [Figure 15] 
	  
	  
	  
	  
FIGURE 15: A Immunoblots representative of cells transfected with wt-NCC gene and 
G394D-NCC gene. Full and dotted arrows point out the mature glycosylated and the non-
mature glycosylated band respectively. α-tubulin was used as housekeeping gene.   B Mature 
glycosylated protein expression calculated in density units normalized for α-tubulin after 24 and 
48 hours of transfection 
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Xenopus laevis oocytes experiments 
 
Expression vectors were created by ligation of the psDeasy BS backbone with an insert 
of hNCC wt, G394D-NCC and EGFP.  A first experiment was performed to assess the 
efficiency of the injection, by using only the EGFP construct.  Oocytes, after 24 hours 
of injection expressed the green fluorescent proteins visualized at the florescent 
microscope. [Figure 16] 
 
 
 
FIGURE 16: X.L. oocyte expressing green fluorescent protein. The animal pole is in the upper 
hemisphere, while the vegetal pole is the white hemisphere. 
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Ø X.L. oocytes western blot  
 
The X.L. oocytes lysate was used to western blot experiments for the detection of the 
NCC protein expression.  Wild-type NCC injected oocytes showed after 24 hours and 
after 48 hours a band around 130KDa while G394D-NCC did not. The band was even 
more predominant at 48hours of injection. [Figure 17] 
	  
FIGURE 17: western blot image of oocytes lysate blotted with an antibody against NCC. 
Around 130KDa wt NCC expresses a higher band of fully glycosylated protein, while mutant 
does not. Antibody against GADPDH was used as loading control. 
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Ø X.L. oocytes immunohistochemistry  
 
In X.L. oocytes injected with either human NCC wild-type RNA or mutated 
(c.1204G>A) RNA, immunohistochemistry experiments showed a difference between 
the phenotypes. Using antibodies against NCC, in oocytes expressing wt-NCC a 
staining for the protein was observed at the membrane surface of the oocytes.  By 
contrast, in those injected with G394D-NCC RNA, antibody against NCC was 
detectable under the membrane surface.  The cell surface of the oocytes was labeled by 
detecting the microvillar actin cytoskeleton with Fluorescein Phalloidine as 
housekeeping marker.  Merged images showed an overlay between actin and NCC in 
wt-NCC expressing oocytes.  No overlay of G394D-NCC oocytes with actin staining 
was found. [Figure 18] 
	  
	  
	  
FIGURE 18: Immunohistochemistry analyses of oocytes injected with 0.05µl H2O as vehicle, 
wt-NCC, G394D-NCC cRNA respectively. Co-labelling with both the antibodies for NCC and 
actin. Actin cytoskeleton is used as housekeeping marker and shows the staining at the 
membrane. wt-NCC stains at the membrane as the overlay with actin is clear, while G394D-
NCC stains under the membrane.  
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Ø X.L. oocytes 22Na+ uptake 
Functional studies were performed by using 22Na+ uptake to confirm the phenotypes.  
Three independent experiments were done in different conditions: controls were oocytes 
injected with water, mutated were oocytes injected with G394D-NCC, and wild-type 
were injected with wt-NCC. Each group was either treated or not with thiazides.  
In physiological conditions, controls group absorbed a low quantity of 22Na+ set as 
100% and when challenged with thiazide treatment showed less, but not significant, 
uptake (without thiazide 100 vs. with thiazide 65.01 p>0.05). wt-NCC oocytes could 
absorb 22Na+ more than 3 folds compared to controls (342.3), meaning that the insertion 
of the protein was effective in terms of reaching the membranes and explicating its 
activity.  When thiazides were added to wt-NCC, the cotransporter activity was 
significantly inhibited resulting in a drop of uptake (without thiazide 342.3 vs. with 
thiazide 63.3 p<0.0001).  By contrast, G394D-NCC resulted in no 22Na+ uptake in both 
conditions, regardless of the presence or absence of thiazides (without thiazide 77.3 vs. 
with thiazide 75 p>0.05) [Figure 19].  
 
	  
FIGURE 19: 22Na+ Uptake in oocytes injected and treated or not treated with thiazides. Control 
group H20: without thiazide 100 vs. with thiazide 65.01 p>0.05; WT NCC: without thiazide 
342.3 vs. with thiazide 63.3 p<0.0001; Mut NCC (G394D-NCC): without thiazide 77.3 vs. with 
thiazide 75 p>0.05  
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This result confirms the relevance of NCC function for Gitelman phenotype: the point 
mutation characterized leads to lack of intrinsic activity of the protein resembling the 
impaired 22Na+ uptake induced by thiazide treatment. 
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DISCUSSION AND CONCLUSIONS 
 
This study aimed at characterizing a novel mutation found in the sodium chloride 
cotransporter in a heterozygous patient affected by Gitelman’s syndrome.  NCC is a 
member of the solute carrier family 12 (SLC12) of electroneutral cation coupled 
cotransporter family (70-72).  This cotransporter shares a highly conserved aminoacid 
sequence with other members of the family. It features twelve transmembrane portions 
harboring a central hydrophobic domain and two cytosolic terminal ends (NH2 and 
COOH) (38).  
Standing from the clinical identification of a patient with a complete biochemical 
characterization pointing to a diagnosis of GS, we performed a genetic analysis for the 
26 exons of SLC12A3 gene. This led to identify two mutations: c.1925G>A 
(Arg642His) and c.1181G>A (Gly394Asp).  The former is one of the most common 
variant described in the syndrome, but the latter has never been described before.  
Since not all the variants are causative of the pathology, this prompted us to investigate 
which was the relevance of the novel mutation (Gly394Asp) for the phenotype and the 
clinical outcome. 
By using bioinformatics tools for the prediction of the mutation impact in the protein 
activity, the novel mutation seems to have a stronger impact compared to the other 
present, in fact the PROVEAN score was -5.71 for G394D vs -4.83 for R642H.  The 
PROVEAN score is a value obtained from a computation analysis which inquires every 
amino acid position of all protein sequences in human and mouse and discriminate and 
predicts the impact of an amino acid substitution in the protein activity.  Hence we 
were prompted to address the novel mutation as a very strong impact for the final 
folding and activity of NCC. 
GS subjects are often heterozygous compound, specifically, to the onset of the disease 
they should carry two different mutations affecting two alleles of an autosome (1,18).  
A question that needs to be answered is what is the specific impact of each mutation in 
the final activity of the protein and the phenotype.   
A mutation can affect the activity of a protein since the very beginning of its 
production.   Nucleotide mutations in DNA can alter amino acids sequence with 
consequences in protein expression or function.  Alterations can be missense and 
nonsense, insertion, deletion, duplication, frameshift mutations or repeat expansion.  
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The single amino acid replacement of glycine with aspartic acid at the position 394 was 
found to have a strong impact in terms of loss of function of the cotransporter.  
Monogenic mutations are responsible for many kidney diseases and usually exhibit a 
genotype-phenotype correlation in single-gene disease of almost 100%.  This means 
that a genetic investigation can predict the diagnosis of an inherited syndrome (73). 
Moreover, amino acid mutations can not only lead to mutated proteins, but also to its 
impaired trafficking, its endocytosis and its degradation (74).  In fact the linear amino 
acids sequence is known to be translated into a three dimensional protein structure 
delineated by alpha-helices and β-sheets strands, which tends to arrange in a specific 
thermodynamically most stable conformation (69).  An alternative amino acid 
sequence confers different properties of the residues, because of its altered electrical 
charge (e.g. positive or negative) or altered size.  Glycine (G) is the smallest neutral 
non polar molecule while at physiological pH Aspartic (D) has acid characteristics with 
a negative charge in the lateral substituent.  Therefore, the aforementioned mutation 
produces a substitution in the amino acid chain, with ensuing possible physical and 
chemical consequences on trafficking from the endoplasmic reticulum to the Golgi 
apparatus.   
To prevent the expression of toxic peptides, the cell organizes complexes mechanisms 
as the recruiting of chaperones molecules that are able to denaturate misfolded proteins 
(75).  In the kidney the enhanced endoplasmic reticulum-associated degradation 
(ERAD) acts triggering complexes of heat shock proteins Hsp70 and other components 
as ubiquitin-ligase, which are still unknown.  By using a yeast model, Needham et al. 
showed that in Gitelman’s syndrome there was a reduction of ER export due to NCC 
misfolding and that ERAD degradation influenced NCC turnover (76).	    
We found that in transfected HEK293 the G394D-NCC induces the production of a 
protein detectable at the western blot but with different characteristics form the NCC 
wild-type.  Similar results were produce by De Jong et al., were they showed through 
de-glycosylation experiments, that the higher band resembled the fully glycosylated 
NCC (PMID 12039972). The absence of the fully glycosylated band in G394D-NCC 
suggests improper folding of the protein, albeit through mechanisms to be defined.  
The incorrect folding could led to lack of exposure of the extracellular loop with the 
two glycosylation sites across the 7th and the 8th domains.  Moreover, the lack of 
glycosylation likely led to impaired trafficking of the protein to the membrane as shown 
by our immunohistochemistry experiments.  
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The Gly394Asp exchange is responsible for the correct folding of the protein by 
embedding a negative charge, which causes a disorder in the energy and in the physical 
properties of the structure.  The resulted peptide is in turns recognized by the ERAD 
system, which therefore induces its early degradation. 
Based on the data described in the study of De Jong, the ER-retained mutated NCC does 
not lack glycosylation, but is core-glycosylated and hence not fully glycosylated (77). 
Consistently, Hoover et al. showed that rat NCC has 404 and 424 asparagines N-linked 
sites critical for the glycosylation of the cotransporter (77-­‐79).  The central region, and 
particularly the 7th and 8th domains, seems to be highly specific for ion translocation and 
for thiazide–binding.  Their external loop containing glycosylation sites are thus 
fundamental for the maturation of the protein and for the selectivity filter efficacy.  A 
mutation in this position is therefore predicted to influence the activity of the protein 
(39,80).  We used X. L. oocytes to better gain insights on the causes leading to an 
aberrant behavior of the protein.  Since they do not express many proteins and thus do 
not develop a huge background, but their apparatus is ready to induce post-translational 
modifications, they are a well established tool to explore biochemical processes as 
protein signaling, transduction, phosphorylation and channels function (63,81).   
Effect of gene mutation on glycosylation 
By comparing in vitro the experiments in HEK293 cells and those in X.L. oocytes, we 
could confirm that wild-type proteins show at the western blot two bands: the core at 
110 KDa and the glycosylated at 130 KDa, whereas the mutant cotransporter lack of the 
higher weight complex in accordance to the previous evidences (77,80).  This finding 
could therefore explain the strong pathogenic impact of the novel mutation that is 
located in the 7th transmembrane fragment.  
Effect of loss of glycosylation on protein 
The immunohistochemical analysis provided evidence supporting the conclusion that 
the mutant protein triggers early ERAD in accordance with previous investigations 
(82,83).  These experiments show that in wild-type injected oocytes, NCC reaches the 
plasma membrane, while, conversely, the mutants showed staining only in the 
intracellular area.  The impaired folding results in an erroneous peptide, which is 
captured by the cytosolic control system, thus enhancing the retrieval for the 
degradation.   
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Effect of mutation on protein function 
22Na+ uptake experiments endorsed the evidence that this mutation is causative of the 
pathology.  When oocytes were incubated in the K+ free medium, these mutants were 
able to uptake only a small quantity of 22Na+ compared to the wild-type (22,58% of total 
wild-type absorption).  The addition of Metolazone, a thiazide-like drug, induced 
blockade of wild-type NCC, which resembled the quantity absorbed to the H2O as 
vehicle injected.  In G394D-NCC Metolazone did not reduced the basal absorption of 
indicating that G394D-NCC was not functional.  The failure of the mutated 
cotransporter to uptake 22Na+ as efficiently as the wild-type indicates the functional 
consequences of the mutation and establishes the inefficiency of G394D-NCC in terms 
proper folding, on trafficking leading to early protein degradation in ERAD.  
Previously functional and expression analysis on oocytes described 3 different classes 
of NCC mutants in Gitelman’s syndrome	  (7,77,84,85).  Accordingly to those categories, 
Class I mutants are partially glycosylated but unable to uptake sodium.  Class II 
mutants have uptake activity and are fully glycosylated but are only partially able to 
reach the surface.  Class III mutants are glycosylated, expressed on the membranes, 
but unable to uptake sodium.  This study show that the novel mutation entails an 
impaired glycosylation of the protein compared to the wild-type moreover, impaired 
trafficking at the membrane, with ensuing impaired the uptake.  Hence, the novel 
mutation identified in this study reasonably could belong to a novel class of impaired 
proteins that are not glycosylated, can not reach the surface and do not function 
properly.   
A recent review by Wang et al. elucidated that mutations have been identified spread all 
over the 26 exons but notwithstanding many attempts, most of them are too rare to 
allow identification of a correlation between genotype and phenotype (38).  As it has 
been speculated that the position of the mutations and their outcome in terms of protein 
expression, glycosylation and phosphorylation could impact the severity of the 
syndrome our study add novel knowledge on the functional role of the 7th -8th 
transmembrane domains (86). 
Occasionally GS phenotype is not correlated with a clear genotype, indeed some deep 
intronic mutations sometimes are not detectable but are translated in inclusion of cryptic 
exons in mRNA which arise in aberrant proteins (87,88).  Moreover, the severity of 
the phenotype has been described to vary widely.  According to Riveira-Munoz et al. 
observed one allele splicing mutation would lead to retained nonfunctional protein, and 
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would be prevalently present in the subgroup of patients screened harboring the most 
severe phenotype and in male subjects (80).  The same observation was done by Lin et 
al., who described the heterogeneity of clinical phenotype in members of a family with 
identical mutations (89).  The gender seems therefore to have a great influence, as 
studies with ovariectomized rats show that NCC plasma abundance is decreases and 
conversely, the treatment with estradiol restores its presence (90,91).  This could be an 
explanation of the milder symptoms observed in GS female patients.   
Notwithstanding an overactivation of the RAAS, GS patients have low blood pressure 
(92).  Cruz et al. hypothesized that inherited mutations in genes involved in the control 
of the sodium reabsorption lower blood pressure (93).  Given that salt wasting is the 
hallmark Gitelman's and Bartter's (BS) syndromes, Ji et al. investigated the presence of 
some genes causative of GS and BS, in the Framingham Heart Study (FHS) offspring 
cohort (4).  They screened the Na-K-2Cl cotransporter gene (SLC12A1), the inward 
rectifier K+ channel gene (KCNJ1) and the SLC12A3, observing the presence of 
functional mutations in one of the three genes with an incidence of 1/64 FHS members.  
They found that FHS individuals carrying those mutations had reduced blood pressure 
(4).  These findings suggest the relevance of genetic mutations that are inherited 
among population with high blood pressure and that can even hide secondary 
hypertension. 
Conclusion 
This study shows that characterization of a novel mutation on NCC can lead not only to 
a better understanding of the molecular mechanisms causing GS but also to 
identification of functional role of the different molecular domains of the NCC.   
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